ARCHIVES

BMS Demands Resignation Of Two ImClone Executives

This article is from The Cancer Letter archive.

Vol. 28 No. | March 8, 2002

Download PDF Visit The Full Archive

Related Articles

Regulatory Agencies: HCFA Proposes Physician Transfer Of Drug Discounts To Medicare, Insurers

April 3, 1998

House Encourages NCI To continue Leadership Role As Coordinator Of Cancer Program

October 8, 1999

Two Second-Line CML Drugs Work Front-Line, Studies Find

January 29, 2010

Zerhouni forms steering committee; Olden to retire.

August 1, 2003

Taxol Recommended For Second Line Therapy In Platinum-Resistant Metastatic Ovarian Cancer

November 20, 1992

Advanced Ovarian Cancer Responds To Irofulven In Phase II Studies

October 26, 2001